Safety, pharmacokinetics (PK), pharmacodynamics (PD) and efficacy of KT-253, a targeted protein degrader of MDM2, in patients with relapsed/refractory (R/R) solid tumors, lymphoma, high grade myeloid malignancies and acute lymphoblastic leukemia (ALL).
Wednesday, June 19, 2024
Dr. Reva Schneider
Click the above link to view the abstract.
ASCO 2024 Poster for Trial 23-05
Related Abstracts
Discover more abstracts for our trials.